1. Home
  2. IMAB vs FCO Comparison

IMAB vs FCO Comparison

Compare IMAB & FCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMAB
  • FCO
  • Stock Information
  • Founded
  • IMAB 2014
  • FCO 1991
  • Country
  • IMAB United States
  • FCO United Kingdom
  • Employees
  • IMAB N/A
  • FCO N/A
  • Industry
  • IMAB Biotechnology: Pharmaceutical Preparations
  • FCO Investment Managers
  • Sector
  • IMAB Health Care
  • FCO Finance
  • Exchange
  • IMAB Nasdaq
  • FCO Nasdaq
  • Market Cap
  • IMAB 79.9M
  • FCO 80.3M
  • IPO Year
  • IMAB 2020
  • FCO N/A
  • Fundamental
  • Price
  • IMAB $0.96
  • FCO $5.97
  • Analyst Decision
  • IMAB Strong Buy
  • FCO
  • Analyst Count
  • IMAB 3
  • FCO 0
  • Target Price
  • IMAB $8.00
  • FCO N/A
  • AVG Volume (30 Days)
  • IMAB 288.7K
  • FCO 100.1K
  • Earning Date
  • IMAB 03-13-2025
  • FCO 01-01-0001
  • Dividend Yield
  • IMAB N/A
  • FCO 14.96%
  • EPS Growth
  • IMAB N/A
  • FCO N/A
  • EPS
  • IMAB N/A
  • FCO 0.43
  • Revenue
  • IMAB $3,313,984.00
  • FCO N/A
  • Revenue This Year
  • IMAB N/A
  • FCO N/A
  • Revenue Next Year
  • IMAB N/A
  • FCO N/A
  • P/E Ratio
  • IMAB N/A
  • FCO $12.30
  • Revenue Growth
  • IMAB N/A
  • FCO N/A
  • 52 Week Low
  • IMAB $0.84
  • FCO $4.73
  • 52 Week High
  • IMAB $2.00
  • FCO $6.63
  • Technical
  • Relative Strength Index (RSI)
  • IMAB 45.33
  • FCO 46.09
  • Support Level
  • IMAB $0.95
  • FCO $5.92
  • Resistance Level
  • IMAB $1.04
  • FCO $6.13
  • Average True Range (ATR)
  • IMAB 0.06
  • FCO 0.11
  • MACD
  • IMAB -0.01
  • FCO -0.02
  • Stochastic Oscillator
  • IMAB 19.88
  • FCO 14.29

About IMAB I-MAB

I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).

About FCO abrdn Global Income Fund Inc.

abrdn Global Income Fund Inc is a closed-end, non-diversified management investment company. The Fund's principal investment objective is to provide high current income by investing predominantly in fixed-income securities. As a secondary investment objective, the Fund seeks capital appreciation, but only when consistent with its principal investment objective. It invests in Government Bonds & Corporate Bonds, and its investments are divided into three categories, Developed Markets, Investment Grade Developing Markets and Sub-Investment Grade Developing Markets.

Share on Social Networks: